

Subject: Medical Science Liaison (MSL) Notes - Introduction of NeuroRelieve

Date: October 15, 2024

Provider: Dr. Amanda Rodriguez

Title: Neurologist

Institution: NeuroWell Neurological Institute

Summary of Key Discussion Points:

1. Introduction:

- Introduced NeuroRelieve as a groundbreaking therapy for the management of chronic migraine.
- Emphasized its unique mechanism targeting trigeminal nerve pathways involved in migraine pathophysiology.

2. Provider's Current Patient Cases:

- Dr. Rodriguez expressed keen interest in innovative approaches for patients with refractory chronic migraines.
- Discussed specific cases where current migraine treatments have shown limited efficacy or intolerable side effects.

3. Efficacy and Clinical Data:

- Presented recent clinical data showcasing NeuroRelieve's ability to reduce migraine frequency by 50% and severity by 30%.
- Highlighted statistically significant improvements in quality of life measures and decreased reliance on rescue medications.

4. Safety Profile:

- Discussed the favorable safety profile of NeuroRelieve, with minimal reported central nervous system side effects.
- Dr. Rodriguez inquired about potential interactions with commonly prescribed neurological medications.

5. Mechanism of Action:

- Explained NeuroRelieve's mechanism, focusing on its targeted modulation of trigeminal nerve hyperactivity.
- Dr. Rodriguez appreciated the drug's novel approach and sought insights into its potential for long-term migraine prevention.

6. Patient Adherence and Education:

- Discussed strategies for enhancing patient adherence through a once-monthly subcutaneous injection.

- Shared patient education materials emphasizing the importance of consistent therapy for sustained migraine relief.

7. Emerging Research and Future Developments:

- Highlighted ongoing research on NeuroRelieve's potential in other headache disorders, such as cluster headaches.
- Discussed plans for exploring combination therapies to address multifactorial migraine triggers.

8. Competitive Landscape:

- Compared NeuroRelieve to existing migraine therapies, emphasizing its targeted mechanism and potential for comprehensive migraine control.
- Discussed the need for individualized treatment plans considering the diverse nature of chronic migraine.

9. Access and Reimbursement:

- Provided updates on access and reimbursement programs for neurological clinics.
- Discussed potential affordability concerns and patient assistance programs.

10. Action Items and Follow-Up:

- Dr. Rodriguez expressed interest in participating in ongoing clinical trials related to NeuroRelieve in migraine management.
- Agreed upon a follow-up in three months to provide additional data and address any ongoing concerns.

11. Closing Remarks:

- Expressed gratitude for Dr. Rodriguez's dedication to advancing migraine care.
- Reiterated commitment to ongoing collaboration and support for the NeuroWell Neurological Institute.